it'll be higher, how much is anyone's guess. I believe closer to $15-20 million and some annual funding for the rights to low impacts in a laundry list of indications. Some nice back end deals and we can get going ADHD trials as well, that was clearly highlighted _"upon receipt of funding" thursday. Maybe they'll be able to hold on to High Impacts. I believe the stock price will react to the cache of the partner as well, which I am unable to predict-easier to say who it won't be.
our best hope is to partner off everything except for ADHD, and then hope they spend the money wisely, and work like mad to make it (ADHD) happen. The Stoll homerun!
Market Data 
Markets 
AI
